ArticleJNCI cancer spectrum2023
The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience.
Jared C Foster et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it